Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis

Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity

(2016) Anette Karle et al.   mAbs

Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes

(2015) Denis Jullien et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)

(2014) A. Blauvelt et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)

(2014) C. Paul et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2)

(2013) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis

(2013) T. Bito et al.   BRITISH JOURNAL OF DERMATOLOGY

Antidrug antibodies in psoriasis: a systematic review

(2013) L. Hsu et al.   BRITISH JOURNAL OF DERMATOLOGY

Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?

(2013) Clara De Simone et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials

(2013) Richard G. B. Langley et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

(2013) Pauline A. van Schouwenburg et al.   Nature Reviews Rheumatology

Immunogenicity/Hypersensitivity of Biologics

(2013) Michael W. Leach et al.   TOXICOLOGIC PATHOLOGY

Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy

(2012) Narendra Chirmule et al.   AAPS Journal

The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings

(2012) David A. Martin et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

(2012) Rosa Parisi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan

(2011) Tsen-Fang Tsai et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis

(2011) A. M. Lin et al.   JOURNAL OF IMMUNOLOGY

Immunotoxicity of monoclonal antibodies

(2010) Jacques Descotes   mAbs

The immunogenicity of humanized and fully human antibodies

(2010) Fiona A. Harding et al.   mAbs

Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the Pathogenesis of Psoriasis

(2010) Pieter C. M. Res et al.   PLoS One

Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin

(2009) C. Johansen et al.   BRITISH JOURNAL OF DERMATOLOGY

IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines

(2009) Consuelo Ortega et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells

(2008) Michelle A. Lowes et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY